FDA approves new indication for Ipsen's Somatuline Depot

French drugmaker Ipsen announced that the US Food and Drug Administration has approved a supplemental indication for Somatuline Depot (lanreotide) injection 120 mg for the treatment of carcinoid syndrome.

This treatment is already approved for the improvement of progression-free survival in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.